What are the key aspects of introduction, staging, diagnosis, and management of parotid adenoid‑cystic carcinoma?

Parotid Adenoid Cystic Carcinoma: Comprehensive Overview

Introduction

Adenoid cystic carcinoma (ACC) of the parotid gland is a rare, slow-growing malignancy characterized by aggressive long-term behavior, high propensity for perineural invasion, and distant metastasis, accounting for 10-15% of salivary gland tumors with an incidence of 3-4.5 cases per million. 1, 2

• ACC predominantly affects women (female to male ratio 3:2) between the 6th and 7th decades of life, with a mean age of 52.69 years 2, 3
• The tumor exhibits insidious, slow-growing behavior with symptoms such as pain and altered sensation frequently associated with advanced disease 2
• Perineural invasion (PNI) is a distinctive hallmark feature that significantly contributes to the tumor's relapse and recurrence rate of approximately 50% 2
• Distant metastasis is the most frequent adverse outcome, occurring at an average of 34.8 months, followed by locoregional metastasis at 27.5 months and local recurrence at 31.3 months 3

Staging and Prognostic Factors

Advanced T stage (T3-T4), positive lymph nodes, solid histologic subtype, distant metastasis, positive surgical margins, extraglandular extension, and pathological grade are the most critical poor prognostic indicators. 3, 4

Key Prognostic Factors:

• Histologic grade: Cribriform/tubular (C-T) type carries better prognosis than solid type; grade II-III tumors have significantly higher locoregional metastasis rates than grade I 5, 4
• Pathological grade and extraglandular extension are independent prognostic factors for disease-free survival (DFS) 4
• pN status and extraglandular extension are independent prognostic factors for overall survival (OS) 4
• Five-year, 10-year, 15-year, and 20-year survival rates are 73.8%, 48.5%, 42.3%, and 26.5%, respectively 3

Molecular Alterations:

• Recurrent molecular alterations include rearrangements involving MYB, MYBL1, and NFIB genes 6
• Copy number alterations affect genes including C-KIT, with mutations impacting NOTCH, PI3KCA, and PTEN signaling pathways 6

Diagnosis

Tissue biopsy via fine needle aspiration biopsy (FNAB) or core needle biopsy (CNB) should be performed to distinguish salivary gland cancers from nonmalignant lesions, with CNB preferred if FNAB is inadequate. 7

Diagnostic Workup:

• Imaging: Preoperative ultrasonography routinely assesses major salivary gland tumor extent with good ultrasound/FNA correlation 8
• Advanced imaging: MRI with contrast from skull base to thorax should be performed for all patients with salivary gland malignancies 7
• PET/CT: May be performed from skull base to mid-thighs for advanced-stage high-grade salivary gland cancers 7
• Pathology reporting: Risk stratification schemes should be used for salivary FNABs with particular attention to high-grade features 7
• Ancillary testing: Immunohistochemical or molecular studies may be performed on FNABs and core needle biopsies to support diagnosis and risk assessment 7

Common Pitfall:

Diagnosis is often challenging and requires a combination of clinical examination, imaging, and histopathology; frozen sections may be used intraoperatively but should not solely guide major decisions like facial nerve resection 7, 8, 2

Management

Surgical Management

Open surgical excision with negative margins is the gold standard and mainstay of treatment for all histologically confirmed parotid ACC. 7, 1

Primary Tumor Resection:

• At least superficial parotidectomy should be performed, with consideration of total or subtotal parotidectomy for any high-grade or advanced (T3-T4) parotid cancer due to risk of intraparotid nodal metastases 7
• Facial nerve preservation should be performed in patients with intact preoperative facial nerve function when a dissection plane can be created between tumor and nerve 7
• Resection of involved facial nerve branches should be performed only when branches are encased or grossly involved by confirmed malignancy or when preoperative facial nerve impairment exists 7
• In practice, the facial nerve was preserved in all cases except those with gross tumor involvement 8

Neck Management:

• Elective neck treatment should be offered over observation in clinically negative necks for T3-T4 tumors and high-grade malignancies 7
• For parotid malignancies, ipsilateral selective neck dissection should include levels 2-4 7
• For cN1 neck, ipsilateral neck dissection of involved and at-risk levels may extend to adjacent levels, up to levels 1-5 7

Recurrent Disease:

• In resectable recurrent locoregional disease without distant metastasis, revision resection with appropriate surgical reconstruction should be offered regardless of prior treatment type 7
• Both initial surgical treatment and repetitive surgical resection of resectable recurrent lesions, including locoregional and lung metastases, result in longer survival 5
• Salvage surgery significantly prolongs disease-specific survival for both locoregional recurrence and lung metastatic recurrence 5
• With resectable recurrent disease and distant metastasis, palliative revision resection may be considered if metastatic disease is not rapidly progressive or imminently lethal 7

Radiation Therapy

Postoperative radiation therapy should be offered to ALL patients with resected adenoid cystic carcinoma, regardless of other features. 7

Indications for Postoperative RT:

• Mandatory for: All resected ACC cases 7
• Also strongly indicated for: High-grade tumors, positive margins, perineural invasion, lymph node metastases, lymphatic or vascular invasion, and T3-T4 tumors 7
• May be offered for: Close margins or intermediate-grade tumors 7

RT Technical Considerations:

• High-dose target should cover the salivary gland surgical bed and appropriate nodal levels 7
• In cases of perineural invasion, the associated nerve(s) may be covered with elective or intermediate dose to the skull base 7
• Elective neck irradiation may be offered to patients with cN0 disease for T3-T4 cancers or high-grade malignancies 7
• Particle therapy (proton, neutron, carbon ion) may be used, though there are no indications for heavy particle therapy over photon or electron therapy 7
• Radiotherapy should be offered to patients who are not surgical candidates due to extent of disease or medical comorbidity 7

Systemic Therapy

No effective systemic therapy is currently FDA-approved for ACC; chemotherapy for parotid tumors has been disappointing, and studies of targeted therapies have not offered significant benefits. 9

• Investigations into immunotherapy, tyrosine kinase inhibitors, and anti-angiogenics are ongoing but no systemic therapy is FDA-approved 6
• Discovery of genetic mutations and biomarkers has encouraged clinical studies targeting specific receptors to prevent tumor proliferation and metastasis 2
• Patients undergoing revision surgery for recurrent disease should be evaluated for potential adjuvant therapy 7

Treatment Goals and Long-Term Outcomes

The major goal of treatment for ACC is long-term survival including cancer-bearing survival, resulting in either natural death or intercurrent-disease death, since judging cure of ACC is almost impossible. 5

• Overall 10-year, 20-year, and 25-year survivals are 63.7%, 27.3%, and 20.0%, respectively 5
• Disease-specific survival at 10,20, and 25 years is 65.7%, 51.2%, and 38.4%, respectively 5
• Disease-free survival at 10,20, and 25 years is only 25.2%, 9.4%, and 9.4%, respectively, highlighting the indolent but persistent nature of this disease 5
• Conducting surgery and cribriform-tubular histologic type are independent prognostic predictors of disease-specific survival 5